Professor Peter Sasieni
Academic Director of King's Clinical Trials Unit
Research interests
- Cancer
Contact details
Biography
Peter Sasieni is Academic Director of King's Clinical Trials Unit and Professor of Cancer Prevention. He leads the cancer prevention group which takes a population perspective to research on cancer screening, early detection, and prevention. The group has sub-teams in behavioural sciences, clinical trials, experimental epidemiology, observational epidemiology and statistics.
Prof Sasieni read mathematics at Cambridge University and a PhD in biostatistics from the University of Washington. He did his post-doctoral training at the Imperial Cancer Research Fund (later Cancer Research UK (CRUK)) in Jack Cuzick's group. The group moved to the Wolfson Institute of Preventive Medicine at Queen Mary University of London where Sasieni became Professor of Cancer Epidemiology & Biostatistics. He joined KCL in 2017. Sasieni has a CRUK programme grant in cancer screening and statistics, is Director of the CRUK KCL Cancer Prevention Trials Unit, and Vice Director of the NIHR Policy Research Unit on Cancer, Awareness, Screening and Early Diagnosis.
Research
Cancer Screening and Statistics Unit
Cancer Screening and Statistics Unit are a group of epidemiologist and cancer researchers studying the causes of or early events in the development of cancer. Our aim is to be able to intervene and prevent cancer or diagnose it whilst still easy to treat.
Cancer Prevention Trials Unit
The Cancer Research UK & King’s College London Cancer Prevention Trials Unit (CPTU), funded by CRUK, specialises in research to advance cancer prevention, early diagnosis and screening
News
Professor Peter Sasieni elected Fellow of The Academy of Medical Sciences
Professor Peter Sasieni FMedSci, Academic Director of King’s Clinical Trials Unit, has been appointed a Fellow of The Academy of Medical Sciences.
People with advanced bowel cancer are less likely to have participated in cancer screenings
Data from the NHS Bowel Cancer Screening Programme and the National Cancer Registry were analysed to study screening participation of people with and without...
RCGP Research Paper of the Year awarded to King's team
A team of researchers from King’s has won the RCGP Research Paper of the Year in the health services category.
King's and NHS cancer screening trial hits 140k volunteer target
Over 140,000 people have flocked to take part in the world’s largest trial of a blood test that can detect more than 50 types of cancer, as part of the latest...
Risk of overdiagnosis low for breast cancer screening
The NHS Breast Screening Programme in England has shown little, if any, evidence of overdiagnosis.
Researchers offer solution to tackle NHS bowel cancer screening backlog
Research suggests that a solution for clearing the backlog of patients in the bowel cancer screening programme awaiting colonoscopy appointments is to raise...
Thousands of people to receive self-testing kits in bladder health check study
The ‘YORKSURe’ trial, being supported by the Cancer Prevention Trials Unit at King’s College London, is investigating whether urine self-testing kits and...
HPV vaccine reduces cervical cancer by 87%
The human papillomavirus (HPV) vaccine reduces cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, confirms a new study.
King's leads the world's largest trial of cancer blood test
The world’s largest trial of a revolutionary new blood test that can detect more than 50 types of cancer before symptoms appear has launched today.
At home kits to check for early cervical cancer launches in London
More than 31,000 women will be offered kits to carry out a check for HPV, also known as “smear tests”, in the privacy and convenience of their own home.
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...
Research
Cancer Screening and Statistics Unit
Cancer Screening and Statistics Unit are a group of epidemiologist and cancer researchers studying the causes of or early events in the development of cancer. Our aim is to be able to intervene and prevent cancer or diagnose it whilst still easy to treat.
Cancer Prevention Trials Unit
The Cancer Research UK & King’s College London Cancer Prevention Trials Unit (CPTU), funded by CRUK, specialises in research to advance cancer prevention, early diagnosis and screening
News
Professor Peter Sasieni elected Fellow of The Academy of Medical Sciences
Professor Peter Sasieni FMedSci, Academic Director of King’s Clinical Trials Unit, has been appointed a Fellow of The Academy of Medical Sciences.
People with advanced bowel cancer are less likely to have participated in cancer screenings
Data from the NHS Bowel Cancer Screening Programme and the National Cancer Registry were analysed to study screening participation of people with and without...
RCGP Research Paper of the Year awarded to King's team
A team of researchers from King’s has won the RCGP Research Paper of the Year in the health services category.
King's and NHS cancer screening trial hits 140k volunteer target
Over 140,000 people have flocked to take part in the world’s largest trial of a blood test that can detect more than 50 types of cancer, as part of the latest...
Risk of overdiagnosis low for breast cancer screening
The NHS Breast Screening Programme in England has shown little, if any, evidence of overdiagnosis.
Researchers offer solution to tackle NHS bowel cancer screening backlog
Research suggests that a solution for clearing the backlog of patients in the bowel cancer screening programme awaiting colonoscopy appointments is to raise...
Thousands of people to receive self-testing kits in bladder health check study
The ‘YORKSURe’ trial, being supported by the Cancer Prevention Trials Unit at King’s College London, is investigating whether urine self-testing kits and...
HPV vaccine reduces cervical cancer by 87%
The human papillomavirus (HPV) vaccine reduces cervical cancer rates by 87% in women who were offered the jab between the ages of 12-13, confirms a new study.
King's leads the world's largest trial of cancer blood test
The world’s largest trial of a revolutionary new blood test that can detect more than 50 types of cancer before symptoms appear has launched today.
At home kits to check for early cervical cancer launches in London
More than 31,000 women will be offered kits to carry out a check for HPV, also known as “smear tests”, in the privacy and convenience of their own home.
Spotlight
How King's continues to tackle cancer and support cancer care and research
Saturday 4 February marks World Cancer Day. In order to honour this key date, we have highlighted some of the most important cancer-themed stories that have...